News-Medical.Net on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...
Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...
Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.
Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...
Q. You recently wrote that testosterone does not increase the risks for heart attacks. But you overlooked the real risk of testosterone therapy: cancer!
Ernie Strauss and Ronald Wakefield, who met through the patient navigation program of Northside Hospital, have built a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results